Purpose: This study was conducted to understand the factors influencing the performance of nurses to identify interventions to promote nursing performance. The study focused on workplace bullying, social interaction anxiety, and positive psychological capital. Methods: Data were collected from 148 nurses who had been working for over six months at four hospitals and analyzed using the SPSS/WIN 21.0 program. Results: Significant differences were found in nursing performance grades by age (F=3.93, p=.010), marital status (t=-2.52, p=.013), current department experience (F=3.72, p=.013). Nursing performance had a negative correlation with social interaction anxiety (r=-.27, p=.001) and positive psychological capital (r=.61, p<.001). Factors affecting nursing performance were positive psychological capital and age, such that the 40~49-year-old group had a relatively higher influence on nursing performance than the 29-year-old group. The explanatory power of regression analysis was 3% (F=47.65, p<.001). Conclusion The results suggest that to improve nursing performance, positive psychological capital based coaching and educational programs would be suitable for nurses and should be applied to the nursing education curriculum.

Survival rate after renal transplantation has increased by using intense immunosuppressive agents and sophisticated operative techniques were introduced but incidences of malignancy is increasing after transplantation. Renal transplanted patients undergo variable malignancy but the acute T-cell lymphoma originating in the face is relative rare. Cyclosporin A is an immunosuppressive agent with selective inhibitory effects on T lymphocytes. It is currently available to use in organ and bone marrow transplantation recipients. We report a case of acute arising T-cell lymphoma on forehead of a 56-years-old male patient. This patient received renal allograft about 15 years ago. And then for recent 3 years, he takes Cyclosporin A 15mg/day due to allograft rejection. Its pathologic finding was diffuse large T-cell type and exhibited homogenecity of the tumor. He has been followed 3 months and no relapse occurred. We report this case with a brief review of literatures.
Allografts ; Bone Marrow Transplantation ; Cyclosporine ; Forehead ; Humans ; Immunosuppressive Agents ; Incidence ; Kidney Transplantation ; Kidney* ; Lymphoma, T-Cell* ; Male ; Recurrence ; Survival Rate ; T-Lymphocytes*

BACKGROUND/AIMS: The introduction of direct-acting antivirals (DAA) in 2013 revolutionized hepatitis C virus (HCV) treatment, offering a cure rate >90%. However, this therapy is expensive, and estimations of the number of chronic HCV-infected (CHC) patients and their treatment costs pre-2013 are therefore essential for creating policies and expanding drug access. Herein, we aimed to investigate the number of HCV-related liver disease patients, their healthcare utilization, their annual direct medical costs, and the interferon-based antiviral treatment rates and costs from 2009 to 2013 in South Korea. METHODS: The National Health Insurance database was reviewed, and patients diagnosed with CHC from 2009 to 2013 were extracted. Data regarding detailed healthcare utilization, prescribed drugs, and direct medical costs were obtained. For annual direct healthcare cost calculations, a prevalence-based approach was used. RESULTS: Overall, 181,768 CHC patients were identified. In 2013, the annual per-patient costs for chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, and the first year post-liver transplant were 895, 1,873, 6,945, and 67,359 United States dollars, respectively. Interferon-based antiviral therapeutics were prescribed to 25,223 patients (13.9%). CONCLUSIONS: Healthcare costs have increased remarkably with increasing liver disease severity. Thus, efforts to stop disease progression are needed. Moreover, the low rate of interferon-based therapy indicates an unmet need for DAA.
Antiviral Agents ; Carcinoma, Hepatocellular ; Costs and Cost Analysis ; Delivery of Health Care* ; Disease Progression ; Health Care Costs* ; Hepacivirus ; Hepatitis C ; Hepatitis C, Chronic* ; Hepatitis, Chronic* ; Humans ; Korea* ; Liver Cirrhosis ; Liver Diseases ; National Health Programs* ; Ribavirin ; United States

Since the reformation of the National Health Insurance Act in 2000, the Health Insurance Review and Assessment Service (HIRA) in the Republic of Korea has performed quality assessments for healthcare providers. The HIRA Value Incentive Program (VIP), established in July 2007, provides incentives for excellent-quality institutions and disincentives for poor-quality ones. The program is implemented based on data collected between July 2007 and December 2009. The goal of the VIP is to improve the overall quality of care and decrease the quality gaps among healthcare institutions. Thus far, the VIP has targeted acute myocardial infarction (AMI) and Caesarian section (C-section) care. The incentives and disincentives awarded to the hospitals by their composite quality scores of the AMI and C-section scores. The results of the VIP showed continuous and marked improvement in the composite quality scores of the AMI and C-section measures between 2007 and 2010. With the demonstrated success of the VIP project, the Ministry of Health and Welfare expanded the program in 2011 to include general hospitals. The HIRA VIP was deemed applicable to the Korean healthcare system, but before it can be expanded further, the program must overcome several major concerns, as follows: inclusion of resource use measures, rigorous evaluation of impact, application of the VIP to the changing payment system, and expansion of the VIP to primary care clinics.
Benchmarking ; Hospitals ; Humans ; *National Health Programs ; Quality Improvement/*economics ; Quality of Health Care/economics ; Reimbursement, Incentive/*organization & administration ; Republic of Korea

Background/Aims: This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives. Methods: A published decision-tree plus Markov model was used to compare the expected costs and quality-adjusted life years (QALY) between one-time universal HCV screening and no screening in the population aged 40–65 years using the National Health Examination (NHE) program. Input parameters were obtained from analyses of the National Health Insurance claims data, Korean HCV cohort data, or from the literature review. The population aged 40–65 years was simulated in a model spanning a lifetime from both the healthcare system and societal perspectives, which included the cost of productivity loss due to HCV-related deaths. The incremental cost-effectiveness ratio (ICER) between universal screening and no screening was estimated. Results: The HCV screening strategy had an ICER of $2,666/QALY and $431/QALY from the healthcare system and societal perspectives, respectively. Both ICERs were far less than the willingness-to-pay threshold of $25,000/QALY, showing that universal screening was highly cost-effective compared to no screening. In various sensitivity analyses, the most influential parameters on cost-effectiveness were the antibodies to HCV (anti-HCV) prevalence, screening costs, and treatment acceptance; however, all ICERs were consistently less than the threshold. If the anti-HCV prevalence was over 0.18%, screening could be cost-effective. Conclusions One-time universal HCV screening in the Korean population aged 40–65 years using NHE program would be highly cost-effective from both healthcare system and societal perspectives.

Purpose: Painful muscle cramps are a common complication in liver cirrhosis patients, and no effective treatment is available.This pilot study aimed to evaluate whether taurine supplementation improves muscle cramps in Korean cirrhotic patients. Materials and Methods: Ten cirrhotic patients who experienced muscle cramps one or more times/week were enrolled in this prospective single-arm study and administered with an oral taurine solution (1 g/50 mL) thrice a day for 4 weeks. Taurine was discontinued for the subsequent 4 weeks. The frequency and intensity of muscle cramps were evaluated using a questionnaire at weeks 0, 2, 4, 6, and 8 after the start of treatment. Results: At baseline, the median frequency of muscle cramps was six times/week, and all patients had severe pain. Muscle cramp scores (frequency×intensity) decreased in seven patients by weeks 4 and 8 after treatment initiation. Compared to baseline muscle cramp scores [median 21, interquartile range (IQR): 8–84], median muscle cramp scores were lower at week 4 (6.5, IQR: 3–12, p=0.126) and week 8 (5, IQR: 1.5–56, p=0.066). All five patients whose baseline plasma taurine levels were below the normal limit showed increased taurine levels at week 4; 60% of them experienced improvements in their muscle cramps. Of the five patients with normal or higher taurine levels, 80% experienced an improvement in symptoms at week 4. The safety and tolerability of the 4-week taurine therapy were excellent. Conclusion Oral taurine therapy for 4 weeks improved muscle cramps safely in cirrhotic patients.

Objectives: This study aimed to evaluate the registered dentists’ program, from the dentist’s perspective, before its nationwide implementation. Methods: In-depth interviews were conducted with 18 dentists who had participated in the registered dentists’ program in G Province. A questionnaire was prepared based on previous research. The data were collected by transcription of interview recordings. Qualitative research methodology was implemented and the data were coded according to the grounded theory. A paradigm model was presented and the core categories were indicated. Results: The findings were organized into 6 categories, 25 subcategories, and 315 codes, based on open coding of the first categorization of collected data. The central phenomenon was found to be the experience of dissatisfaction with the program. The causal conditions were shown as problems of the program, while contextual and intervening conditions were shown as passive participation of dentists and positive effects of the program, respectively. The action/interaction strategies were summarized as an improvement plan and the consequence was an increased intention to participate. Conclusions The study proposes the need to strengthen primary dental care through this registered dentists’ program, by performing continuous evaluations. The standards and guidelines, cooperation of participants, and appropriate compensation should be considered to promote successful implementation.

Objectives: This study aimed to evaluate the registered dentists’ program, from the dentist’s perspective, before its nationwide implementation. Methods: In-depth interviews were conducted with 18 dentists who had participated in the registered dentists’ program in G Province. A questionnaire was prepared based on previous research. The data were collected by transcription of interview recordings. Qualitative research methodology was implemented and the data were coded according to the grounded theory. A paradigm model was presented and the core categories were indicated. Results: The findings were organized into 6 categories, 25 subcategories, and 315 codes, based on open coding of the first categorization of collected data. The central phenomenon was found to be the experience of dissatisfaction with the program. The causal conditions were shown as problems of the program, while contextual and intervening conditions were shown as passive participation of dentists and positive effects of the program, respectively. The action/interaction strategies were summarized as an improvement plan and the consequence was an increased intention to participate. Conclusions The study proposes the need to strengthen primary dental care through this registered dentists’ program, by performing continuous evaluations. The standards and guidelines, cooperation of participants, and appropriate compensation should be considered to promote successful implementation.

Background/Aims: To eliminate hepatitis C virus (HCV) infection, improving public knowledge of and access to HCV screening and treatment is essential. The aim of this study was to evaluate the knowledge of and testing rate for HCV and the opinions about the inclusion of the HCV test in the National Health Examination (NHE) among the general population in South Korea. Methods: A telephone interview survey was conducted by an independent research company using a 16 item-questionnaire (demographics, knowledge of HCV, testing and results, need for screening) in May 2019. The sample population consisted of 1,003 adult Korean resi-dents adjusted by age, sex, and area according to the stan-dard Korean population in 2019. Results: Among the 1,003 participants (505 women, mean age of 47.9 years), 56.4% recognized HCV; 44.4% understood that HCV is transmit-table, and 56.8% thought that HCV is curable by medication. The recognition rate tended to increase with an increasing level of education. Testing for anti-HCV antibodies was re-ported by 91 people (9.1%); among them, 10 people (11.0%) reported a positive result, and eight people received treat-ment. The common reasons for HCV testing were a health check-up (58.5%), a physician’s recommendation (11.0%) and elevated liver enzyme levels (10.7%). The majority of the population (75.1%) agreed with the integration of HCV into the NHE. Conclusions The level of knowledge of HCV is suboptimal, and the self-reported testing rate for HCV is less than 10%; however, once HCV infection is diagnosed, the treatment rate seems to be high in South Korea. More active campaigns and effective screening are needed.

Silk peptide, the hydrolysate of silk protein derived from cocoons, has been employed as a biomedical material and is believed to be safe for human use. Silk peptide display various bioactivities, including anti-inflammatory, immune-regulatory, anti-tumor, anti-viral, and anti-bacterial. Although earlier investigations demonstrated that silk peptide stimulates macrophages and the production of pro-inflammatory cytokines, its effect on natural killer (NK) cell function has not yet been explored. In this study, we initially confirmed that silk peptide enhances NK cell activity in vitro and ex vivo. To assess the modulatory activity of silk peptide on NK cells, mice were fed various amounts of a silk peptide-supplemented diet for 2 months and the effects on immune stimulation, including NK cell activation, were evaluated. Oral administration of silk peptide significantly enhanced the proliferation of mitogen- or IL-2-stimulated splenocytes. In addition, oral silk peptide treatment enhanced the frequency and degree of maturation of NK cells in splenocytes. The same treatment also significantly enhanced the target cell cytolytic activity of NK cells, which was determined by cell surface CD107a expression and intracellular interferon-γ expression. Finally, oral administration of silk peptide stimulated T helper 1-type cytokine expression from splenic lymphocytes. Collectively, our results suggest that silk peptide potentiates NK cell activity in vivo and could be used as a compound for immune-modulating anti-tumor treatment.
Administration, Oral* ; Animals ; Cytokines ; Diet ; Humans ; In Vitro Techniques ; Killer Cells, Natural* ; Lymphocytes ; Macrophages ; Mice ; Silk*